Gememtech Group Introduced Outcomes of ACTEMRA

Genentech, a member of the Roche Group introduced the fact that SUMMACTA study submitted its primary endpoint, showing equivalent performance (non-inferiority) of a typical subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly when compared with 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.

An equivalent proportion of rheumatoid arthritis (RA) affected individuals in each association accomplished an ACR20 result at Week 24, a measure symbolizing development in the range of tender and swollen joints, pain scale, patients' and physicians' evaluation of enchantment and certain lab markers.

"We are precisely very satisfied with these data revealing that in fact subcutaneous administration of ACTEMRA provides clinically valuable and equivalent outcome into the IV infusion," said Hal Barron, M.D., chief medicinal official and head, Global Product Development. "This could provide affected individuals and their doctors, which includes an important additional treatment method."